表紙
市場調査レポート

心筋線維症:パイプライン製品の分析

Cardiac Fibrosis - Pipeline Review, H1 2015

発行 Global Markets Direct 商品コード 269898
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
心筋線維症:パイプライン製品の分析 Cardiac Fibrosis - Pipeline Review, H1 2015
出版日: 2015年05月20日 ページ情報: 英文 67 Pages
概要

心筋線維症とは、心臓線維芽細胞の異常増殖による心臓弁の異常肥大です。症状には、胸の痛み、腹部膨満、吐き気および倦怠感などがあります。

当レポートでは、心筋線維症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

心筋線維症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

心筋線維症:企業で開発中の治療薬

心筋線維症:大学/機関で研究中の治療薬

心筋線維症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 後期段階の製品

心筋線維症:企業で開発中の製品

心筋線維症:大学/機関で開発中の製品

心筋線維症の治療薬開発に従事している企業

  • Merck & Co., Inc.
  • BioLineRx, Ltd.
  • Compugen Ltd.
  • Digna Biotech, S.L.
  • Promedior, Inc.
  • miRagen Therapeutics, Inc
  • Fibrotech Therapeutics Pty. Ltd.
  • vida therapeutics inc
  • CCRP Therapeutics GmbH

心筋線維症:治療薬の評価

  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • CARD-024
  • P-17
  • disitertide
  • CGEN-856
  • PRM-151
  • MGN-4220
  • PN1-Ab
  • FT-011
  • 末端器官障害向け治療
  • TM-544
  • CGEN-856S
  • 線維症向け薬剤
  • CYP11B2阻害剤プログラム

心筋線維症:パイプラインのアップデート

心筋線維症:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6734IDB

Summary

Global Markets Direct's, 'Cardiac Fibrosis - Pipeline Review, H1 2015', provides an overview of the Cardiac Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cardiac Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cardiac Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cardiac Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cardiac Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Cardiac Fibrosis - Overview
    • Pipeline Products for Cardiac Fibrosis - Comparative Analysis
  • Cardiac Fibrosis - Therapeutics under Development by Companies
  • Cardiac Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Cardiac Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cardiac Fibrosis - Products under Development by Companies
  • Cardiac Fibrosis - Products under Investigation by Universities/Institutes
  • Cardiac Fibrosis - Companies Involved in Therapeutics Development
    • AstraZeneca PLC
    • BioLineRx, Ltd.
    • Daiichi Sankyo Company, Limited
    • Digna Biotech, S.L.
    • Galectin Therapeutics, Inc.
    • miRagen Therapeutics, Inc.
    • ProMetic Life Sciences Inc.
  • Cardiac Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AZ-876 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CARD-024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-856 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • disitertide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GR-MD-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-4220 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-17 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4050 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PN1-Ab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-20102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TM-5441 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cardiac Fibrosis - Recent Pipeline Updates
  • Cardiac Fibrosis - Dormant Projects
  • Cardiac Fibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cardiac Fibrosis, H1 2015
  • Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Investigation by Universities/Institutes, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Investigation by Universities/Institutes, H1 2015
  • Cardiac Fibrosis - Pipeline by AstraZeneca PLC, H1 2015
  • Cardiac Fibrosis - Pipeline by BioLineRx, Ltd., H1 2015
  • Cardiac Fibrosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
  • Cardiac Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015
  • Cardiac Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015
  • Cardiac Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015
  • Cardiac Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Cardiac Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015
  • Cardiac Fibrosis - Dormant Projects, H1 2015

List of Figures

  • Number of Products under Development for Cardiac Fibrosis, H1 2015
  • Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top